Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Easily share your publications and get. JPG' alt='Half Life 1 Patch 1.1.0.4' title='Half Life 1 Patch 1.1.0.4' />FDA prescribing information, side effects and uses. Multiple Myeloma. Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma MM. Revlimid is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation auto HSCT. Myelodysplastic Syndromes. Revlimid is indicated for the treatment of patients with transfusion dependent anemia due to low or intermediate 1 risk myelodysplastic syndromes MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Mantle Cell Lymphoma. Revlimid is indicated for the treatment of patients with mantle cell lymphoma MCL whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. Half Life 1 Patch 1.1.0.4' title='Half Life 1 Patch 1.1.0.4' />DESCRIPTION. REVLIMID, a thalidomide analogue, is an immunomodulatory agent with antiangiogenic and antineoplastic properties. The chemical name is 34amino1oxo 1. Limitations of Use. Revlimid is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials see Warnings and Precautions 5. Revlimid Dosage and Administration. Revlimid should be taken orally at about the same time each day, either with or without food. Revlimid capsules should be swallowed whole with water. The capsules should not be opened, broken, or chewed. Multiple MyelomaRevlimid Combination Therapy. The recommended starting dose of Revlimid is 2. Days 1 2. 1 of repeated 2. Refer to Section 1. For patients 7. Clinical Studies 1. Fairly Oddparents Season 0. Treatment should be continued until disease progression or unacceptable toxicity. In patients who are not eligible for auto HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto HSCT eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a Revlimid containing therapy see Warnings and Precautions 5. Dose Adjustments for Hematologic Toxicities During MM Treatment. Dose modification guidelines, as summarized in Table 1 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to Revlimid. Table 1 Dose Adjustments for Hematologic Toxicities for MMPlatelet counts. Thrombocytopenia in MMWhen Platelets. Recommended Course. Days 1 2. 1 of repeated 2. Fall to lt 3. 0,0. LInterrupt Revlimid treatment, follow CBC weekly. Return to 3. 0,0. LResume Revlimid at next lower dose. Do not dose below 2. For each subsequent drop lt 3. LInterrupt Revlimid treatment. Return to 3. 0,0. LResume Revlimid at next lower dose. Do not dose below 2. Absolute Neutrophil counts ANCNeutropenia in MMWhen Neutrophils. Recommended Course. Days 1 2. 1 of repeated 2. Fall to lt 1. 00. LInterrupt Revlimid treatment, follow CBCweekly. Return to 1,0. 00mc. L and neutropenia is the only toxicity. Resume Revlimid at 2. Return to 1,0. 00mc. L and if other toxicity. Resume Revlimid at next lower dose. Donot dose below 2. For each subsequent drop lt 1,0. LInterrupt Revlimid treatment. Return to 1,0. 00mc. LResume Revlimid at next lower dose. Do not dose below 2. Revlimid Maintenance Therapy Following Auto HSCTFollowing auto HSCT, initiate Revlimid maintenance therapy after adequate hematologic recovery ANC 1. L andor platelet counts 7. L. The recommended starting dose of Revlimid is 1. Days 1 2. 8 of repeated 2. After 3 cycles of maintenance therapy, the dose can be increased to 1. Dose Adjustments for Hematologic Toxicities During MM TreatmentDose modification guidelines, as summarized in Table 2 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to Revlimid. Table 2 Dose Adjustments for Hematologic Toxicities for MMPlatelet countsThrombocytopenia in MMWhen Platelets. Recommended Course. Fall to lt 3. 0,0. LInterrupt Revlimid treatment, follow CBC weekly. Keygen Rhino 5 Mac here. Return to 3. 0,0. LResume Revlimid at next lower dose, continuously for Days 1 2. If at the 5 mg daily dose,For a subsequent drop lt 3. LInterrupt Revlimid treatment. Do not dose below 5 mg daily for Day 1 to 2. Return to 3. 0,0. LResume Revlimid at 5 mg daily for Days 1 to 2. Do not dose below 5 mg daily for Day 1 to 2. Absolute Neutrophil counts ANCNeutropenia in MMWhen Neutrophils. Recommended Course. Fall to lt 5. 00mc. LInterrupt Revlimid treatment, follow CBC weekly. Return to 5. 00mc. LResume Revlimid at next lower dose,continuously for Days 1 2. If at 5 mg daily dose,For a subsequent drop lt 5. LInterrupt Revlimid treatment. Do not dose below 5 mg daily for Days 1 to 2. Return to 5. LResume Revlimid at 5 mg daily for Days 1 to 2. Do not dose below 5 mg daily for Days 1 to 2. Other Toxicities in MMFor other Grade 34 toxicities judged to be related to Revlimid, hold treatment and restart at the physicians discretion at next lower dose level when toxicity has resolved to Grade 2. Starting Dose Adjustment for Renal Impairment in MMsee Dosage and Administration 2. Myelodysplastic Syndromes. The recommended starting dose of Revlimid is 1. Treatment is continued or modified based upon clinical and laboratory findings. Dose Adjustments for Hematologic Toxicities During MDS Treatment. Patients who are dosed initially at 1. Platelet counts. If thrombocytopenia develops WITHIN 4 weeks of starting treatment at 1. MDSIf baseline 1. LWhen Platelets. Recommended Course. Fall to lt 5. 0,0. LInterrupt Revlimid treatment. Return to 5. 0,0. LResume Revlimid at 5 mg daily. If baseline lt 1. LWhen Platelets. Recommended Course. Fall to 5. 0 of the baseline value. Interrupt Revlimid treatment. If baseline 6. 0,0. L andreturns to 5. LResume Revlimid at 5 mg daily. If baseline lt 6. L andreturns to 3. LResume Revlimid at 5 mg daily. If thrombocytopenia develops AFTER 4 weeks of starting treatment at 1. MDSWhen Platelets. Recommended Courselt 3. L or lt 5. 0,0. Lwith platelet transfusions. Interrupt Revlimid treatment. Return to 3. 0,0. Lwithout hemostatic failureResume Revlimid at 5 mg daily. Patients who experience thrombocytopenia at 5 mg daily should have their dosage adjusted as follows If thrombocytopenia develops during treatment at 5 mg daily in MDSWhen Platelets. Recommended Courselt 3. L or lt 5. 0,0. Lwith platelet transfusions. Interrupt Revlimid treatment. Return to 3. 0,0. Lwithout hemostatic failureResume Revlimid at 2. Patients who are dosed initially at 1. Absolute Neutrophil counts ANCIf neutropenia develops WITHIN 4 weeks of starting treatment at 1. MDSIf baseline ANC 1,0. LWhen Neutrophils. Recommended Course. Fall to lt 7. 50mc. LInterrupt Revlimid treatment. Return to 1,0. 00mc. LResume Revlimid at 5 mg daily. If baseline ANC lt 1,0. LWhen Neutrophils. Recommended Course. Fall to lt 5. 00mc. LInterrupt Revlimid treatment. Return to 5. 00mc. LResume Revlimid at 5 mg daily. If neutropenia develops AFTER 4 weeks of starting treatment at 1. MDSWhen Neutrophils. Recommended Courselt 5. L for 7 days or lt 5. Lassociated with fever 3. CInterrupt Revlimid treatment. Return to 5. 00mc. LResume Revlimid at 5 mg daily. Patients who experience neutropenia at 5 mg daily should have their dosage adjusted as follows If neutropenia develops during treatment at 5 mg daily in MDSWhen Neutrophils. Recommended Courselt 5. L for 7 days or lt 5. Lassociated with fever 3. CInterrupt Revlimid treatment. Return to 5. 00mc. LResume Revlimid at 2. Other Grade 3 4 Toxicities in MDSFor other Grade 34 toxicities judged to be related to Revlimid, hold treatment and restart at the physicians discretion at next lower dose level when toxicity has resolved to Grade 2. Sodium valproate C8.